MCID: ADL096
MIFTS: 60

Adult Hepatocellular Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Rare diseases

Aliases & Classifications for Adult Hepatocellular Carcinoma

MalaCards integrated aliases for Adult Hepatocellular Carcinoma:

Name: Adult Hepatocellular Carcinoma 12 15
Adult Primary Hepatocellular Carcinoma 12 70
Hepatocellular Carcinoma, Adult 6
Adult Hepatoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0070328
NCIt 50 C7956
UMLS 70 C0279607

Summaries for Adult Hepatocellular Carcinoma

Disease Ontology : 12 A hepatocellular carcinoma that is characterized by hepatic mass, abdominal pain and, in advanced stages, jaundice, cachexia and liver failure and often develops in the setting of chronic necro-inflammation.

MalaCards based summary : Adult Hepatocellular Carcinoma, also known as adult primary hepatocellular carcinoma, is related to hepatocellular carcinoma and pediatric hepatocellular carcinoma, and has symptoms including fever, abdominal pain and icterus. An important gene associated with Adult Hepatocellular Carcinoma is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Sodium citrate and Tamoxifen have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and colon, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Adult Hepatocellular Carcinoma

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Adult Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 323)
# Related Disease Score Top Affiliating Genes
1 hepatocellular carcinoma 29.4 TP53 TERT PIK3CA PDGFRL LOC110806263 KRAS
2 pediatric hepatocellular carcinoma 11.2
3 embryonal sarcoma 10.4 TP53 CTNNB1 AXIN1
4 vulvar intraepithelial neoplasia 10.4 TP53 CTNNB1 CDKN2A
5 esophagus verrucous carcinoma 10.4 TP53 CDKN2A
6 bowenoid papulosis 10.4 TERT CDKN2A
7 cecal benign neoplasm 10.4 TERT CDKN2A
8 human papillomavirus infectious disease 10.4 TP53 TERT CDKN2A
9 cecum adenoma 10.4 TERT CDKN2A
10 ovarian seromucinous carcinoma 10.4 TP53 CDKN2A
11 penile benign neoplasm 10.4 TP53 PIK3CA CDKN2A
12 bone squamous cell carcinoma 10.4 TP53 CTNNB1 CDKN2A
13 malignant spiradenoma 10.4 TP53 PIK3CA CDKN2A
14 vulva squamous cell carcinoma 10.4 TP53 PIK3CA CDKN2A
15 meningioma, radiation-induced 10.4 TERT PIK3CA AKT1
16 ovarian clear cell adenofibroma 10.4 PIK3CA KRAS
17 acanthoma 10.4 TP53 PIK3CA CDKN2A
18 lung oat cell carcinoma 10.4 TP53 PIK3CA AKT1
19 myoepithelial carcinoma 10.4 TP53 PIK3CA HRAS
20 parathyroid carcinoma 10.4 TERT CTNNB1 APC
21 hair follicle neoplasm 10.4 CTNNB1 CREBBP AXIN1
22 keratosis, seborrheic 10.4 TP53 PIK3CA CDKN2A
23 desmoid tumor 10.3 CTNNB1 CDKN2A APC
24 duodenal benign neoplasm 10.3 HRAS APC
25 tonsil cancer 10.3 TP53 PIK3CA CDKN2A
26 endocervical adenocarcinoma 10.3 TP53 PIK3CA CDKN2A
27 mucosal melanoma 10.3 TP53 TERT CDKN2A
28 periosteal osteogenic sarcoma 10.3 TP53 GNAS
29 breast juvenile papillomatosis 10.3 PIK3CA GNAS AKT1
30 penile disease 10.3 TP53 CDKN2A AKT1
31 spitz nevus 10.3 TP53 HRAS CDKN2A
32 enchondroma 10.3 IDH2 IDH1
33 squamous cell papilloma 10.3 TP53 HRAS CDKN2A
34 hepatic flexure cancer 10.3 KRAS HRAS
35 adult malignant schwannoma 10.3 TP53 HRAS CDKN2A
36 megaesophagus 10.3 TP53 FGFR1 CDKN2A
37 bilateral breast cancer 10.3 TP53 PIK3CA CDKN2A
38 nasal cavity cancer 10.3 TP53 HRAS CDKN2A
39 endocervical carcinoma 10.3 TP53 PIK3CA CTNNB1 CDKN2A
40 pleural cancer 10.3 TP53 CDKN2A AKT1
41 central nervous system benign neoplasm 10.3 TP53 IDH1 CTNNB1
42 signet ring basal cell carcinoma 10.3 KRAS HRAS
43 cobblestone retinal degeneration 10.3 KRAS HRAS
44 frontal lobe neoplasm 10.3 TP53 IDH1
45 nodular malignant melanoma 10.3 TP53 HRAS CDKN2A
46 low-grade astrocytoma 10.3 TP53 IDH1 CDKN2A
47 gliofibroma 10.3 TP53 IDH1 CDKN2A
48 spitzoid melanoma 10.3 TERT HRAS CDKN2A
49 spinal cord oligodendroglioma 10.3 TP53 IDH1 FGFR1
50 endometrial serous adenocarcinoma 10.3 TP53 PIK3CA KRAS

Graphical network of the top 20 diseases related to Adult Hepatocellular Carcinoma:



Diseases related to Adult Hepatocellular Carcinoma

Symptoms & Phenotypes for Adult Hepatocellular Carcinoma

UMLS symptoms related to Adult Hepatocellular Carcinoma:


fever; abdominal pain; icterus; malaise

GenomeRNAi Phenotypes related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

26 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.42 HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.42 HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.42 KRAS
4 Decreased viability GR00106-A-0 10.42 KRAS
5 Decreased viability GR00221-A-1 10.42 AKT1 FGFR1 HRAS KRAS PIK3CA CDKN2A
6 Decreased viability GR00221-A-2 10.42 AKT1 FGFR1 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.42 AKT1 HRAS CDKN2A
8 Decreased viability GR00221-A-4 10.42 AKT1 PIK3CA CDKN2A
9 Decreased viability GR00249-S 10.42 AKT1
10 Decreased viability GR00301-A 10.42 KRAS
11 Decreased viability GR00381-A-1 10.42 KRAS
12 Decreased viability GR00386-A-1 10.42 FGFR1
13 Decreased viability GR00402-S-2 10.42 PIK3CA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.83 KRAS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.83 APC
16 Increased shRNA abundance (Z-score > 2) GR00366-A-14 9.83 IGF2R
17 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.83 IGF2R
18 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.83 IDH2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.83 IDH2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.83 IDH2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.83 APC
22 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.83 IDH2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.83 APC
24 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.83 IGF2R
25 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.83 AKT1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-216 9.83 IDH2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.83 KRAS
28 Increased shRNA abundance (Z-score > 2) GR00366-A-27 9.83 IDH2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.83 IDH2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.83 CTNNB1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.83 IGF2R
32 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.83 PIK3CA AKT1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.83 KRAS
34 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.83 AKT1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.83 IDH2
36 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.83 AKT1
37 Decreased cell migration GR00055-A-1 9.33 AKT1
38 Decreased cell migration GR00055-A-3 9.33 HRAS PIK3CA

MGI Mouse Phenotypes related to Adult Hepatocellular Carcinoma:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.51 AKT1 APC AXIN1 CASP8 CDKN2A CREBBP
2 cardiovascular system MP:0005385 10.49 AKT1 APC AXIN1 CASP8 CDKN2A CREBBP
3 behavior/neurological MP:0005386 10.47 AKT1 APC AXIN1 CDKN2A CREBBP CTNNB1
4 cellular MP:0005384 10.46 AKT1 APC AXIN1 CASP8 CDKN2A CREBBP
5 homeostasis/metabolism MP:0005376 10.45 AKT1 APC CASP8 CDKN2A CNOT9 CREBBP
6 endocrine/exocrine gland MP:0005379 10.43 AKT1 APC CASP8 CDKN2A CREBBP CTNNB1
7 embryo MP:0005380 10.4 AKT1 APC AXIN1 CASP8 CDKN2A CNOT9
8 mortality/aging MP:0010768 10.38 AKT1 APC AXIN1 CASP8 CDKN2A CREBBP
9 hematopoietic system MP:0005397 10.37 AKT1 APC CASP8 CDKN2A CREBBP CTNNB1
10 immune system MP:0005387 10.35 AKT1 APC CASP8 CDKN2A CREBBP CTNNB1
11 nervous system MP:0003631 10.31 AKT1 APC AXIN1 CASP8 CDKN2A CNOT9
12 craniofacial MP:0005382 10.3 APC AXIN1 CREBBP CTNNB1 FGFR1 GNAS
13 digestive/alimentary MP:0005381 10.3 APC AXIN1 CDKN2A CREBBP CTNNB1 FGFR1
14 integument MP:0010771 10.3 AKT1 APC CASP8 CDKN2A CREBBP CTNNB1
15 neoplasm MP:0002006 10.25 AKT1 APC CASP8 CDKN2A CREBBP CTNNB1
16 liver/biliary system MP:0005370 10.24 AKT1 APC CASP8 CDKN2A CREBBP CTNNB1
17 muscle MP:0005369 10.23 AKT1 APC CASP8 CDKN2A CREBBP CTNNB1
18 limbs/digits/tail MP:0005371 10.21 APC AXIN1 CREBBP CTNNB1 FGFR1 GNAS
19 hearing/vestibular/ear MP:0005377 10.11 APC AXIN1 CTNNB1 FGFR1 GNAS KRAS
20 normal MP:0002873 10.1 AKT1 APC AXIN1 CREBBP CTNNB1 FGFR1
21 no phenotypic analysis MP:0003012 10.02 CDKN2A CNOT9 CTNNB1 FGFR1 GNAS HRAS
22 renal/urinary system MP:0005367 9.96 APC AXIN1 CASP8 CTNNB1 FGFR1 GNAS
23 reproductive system MP:0005389 9.9 AKT1 APC AXIN1 CDKN2A CTNNB1 FGFR1
24 respiratory system MP:0005388 9.77 AKT1 AXIN1 CASP8 CDKN2A CREBBP CTNNB1
25 skeleton MP:0005390 9.55 AKT1 APC AXIN1 CDKN2A CREBBP CTNNB1

Drugs & Therapeutics for Adult Hepatocellular Carcinoma

Drugs for Adult Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium citrate Approved, Investigational Phase 3 68-04-2
2
Tamoxifen Approved Phase 3 10540-29-1 2733526
3
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
4
Pravastatin Approved Phase 3 81093-37-0 54687
5
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
6
Ethiodized oil Approved, Investigational Phase 3 8008-53-5
7
Iodine Approved, Investigational Phase 3 7553-56-2 807
8
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
9
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
10
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
11
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
12
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
13
Chlorotrianisene Investigational, Withdrawn Phase 3 569-57-3 11289
14
Cadexomer iodine Experimental Phase 3 94820-09-4
15
Nolatrexed Investigational Phase 3 147149-76-6
16 Citrate Phase 3
17 Antineoplastic Agents, Hormonal Phase 3
18 Estrogens Phase 3
19 Estrogen Receptor Antagonists Phase 3
20 Estrogen Antagonists Phase 3
21 Estrogen Receptor Modulators Phase 3
22 Anticholesteremic Agents Phase 3
23 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
24 Lipid Regulating Agents Phase 3
25 Hypolipidemic Agents Phase 3
26 Central Nervous System Stimulants Phase 3
27 Contraceptive Agents Phase 3
28 Contraceptives, Oral Phase 3
29
Megestrol Phase 3 3562-63-8 3080587 19090
30 Vitamin B9 Phase 3
31 Folic Acid Antagonists Phase 3
32 Vitamin B Complex Phase 3
33 Folate Phase 3
34 Antibiotics, Antitubercular Phase 3
35
Liposomal doxorubicin Phase 3 31703
36 Anti-Bacterial Agents Phase 3
37 Liver Extracts Phase 3
38 Protein Kinase Inhibitors Phase 3
39
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
40
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
41
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
42
Triamcinolone Approved, Vet_approved Phase 1, Phase 2 124-94-7 31307
43
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
44
Octreotide Approved, Investigational Phase 2 83150-76-9 6400441 383414
45
Epirubicin Approved Phase 2 56420-45-2 41867
46
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
47
Ethanol Approved Phase 2 64-17-5 702
48
Lenograstim Approved, Investigational Phase 2 135968-09-1
49
Melphalan Approved Phase 2 148-82-3 4053 460612
50
Fluorouracil Approved Phase 2 51-21-8 3385

Interventional clinical trials:

(show top 50) (show all 141)
# Name Status NCT ID Phase Drugs
1 A Randomized Clinical Trial Evaluating the Benefits of Doxorubicin Chemoembolization Versus Systemic Doxorubicin in Patients With Unresectable, Advanced Hepatocellular Carcinoma Unknown status NCT00079027 Phase 3 doxorubicin hydrochloride
2 Randomised Trial of Adjuvant Hepatic Intra-Arterial Iodine-131-Lipiodol Following Curative Resection of Hepatocellular Carcinoma Unknown status NCT00027768 Phase 3
3 TACE-2: A Randomized Placebo-Controlled, Double Blinded, Phase III Trial of Sorafenib in Combination With Transarterial Chemoembolization in Hepatocellular Cancer Unknown status NCT01324076 Phase 3 doxorubicin-eluting beads;sorafenib tosylate
4 Randomised Trial of Tamoxifen Versus Placebo for the Treatment of Inoperable Hepatocellular Carcinoma Completed NCT00003424 Phase 3 tamoxifen citrate
5 A Double-Blind, Randomized, Phase II/III Study Comparing the Use of Chemoembolization Combined With Sunitinib Against Chemoembolization Combined With a Placebo in Patients With Hepatocellular Carcinoma (SATURNE) Completed NCT01164202 Phase 2, Phase 3 sunitinib malate;Placebo
6 A Prospectively Randomized Controlled Clinical Trial Comparing TheraSphere With Cisplatin-Based TACE (Trans Arterial Chemo Embolization) in the Management of Advanced Stage, Unresectable Hepatocellular Carcinoma (HCC) Completed NCT00109954 Phase 3 cisplatin
7 Randomized Phase III Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma Completed NCT01075555 Phase 3 pravastatin sodium;sorafenib tosylate
8 Randomized Double Blind Trial Of Megestrol Acetate Versus Placebo For The Treatment Of Inoperable Hepatocellular Carcinoma Completed NCT00041275 Phase 3 megestrol acetate
9 A Phase III Randomized Controlled Study Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma (HCC) Treated With THYMITAQ to Patients Treated With Doxorubicin Completed NCT00012324 Phase 3 doxorubicin hydrochloride;nolatrexed dihydrochloride
10 Adjuvant Treatment by Intra-arterial Injection of Lipiodol-labeled Iodine-131 in Preventing Recurrence of Hepatocellular Carcinoma After Curative Treatment Completed NCT00870558 Phase 3 ethiodized oil
11 A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study) Completed NCT01829035 Phase 3
12 Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma Active, not recruiting NCT01730937 Phase 3 sorafenib tosylate
13 Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Active, not recruiting NCT01015833 Phase 3 Doxorubicin Hydrochloride;Sorafenib Tosylate
14 Sorafenib in the First Line Treatment of Advanced Hepatocellular Carcinoma With Child-Pugh Liver Function Class B: Multicentre Phase 3 Randomized Trial Terminated NCT01405573 Phase 3 sorafenib
15 Proof-of-Concept Phase II Study to Evaluate the Anti-Tumor Activity of Sorafenib Along With Pathological and Molecular Changes in Tumor Samples From Patients With Resectable Hepatocellular Carcinoma Unknown status NCT01182272 Phase 2 sorafenib tosylate
16 Phase II Study of TLC D-99 for Hepatobiliary Carcinomas Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
17 Hepatocellular Carcinoma Family of Tumours In Children / Adolescents and Young Adults Unknown status NCT00276705 Phase 2 cisplatin;cyclophosphamide;doxorubicin hydrochloride;thalidomide
18 A Phase II Trial of Oxaliplatin/Adriamycin/5 Fluorouracil in Continuous Infusion / Interferon α-2b (OXAFI) Combination as Neoadjuvant Therapy in Unresectable Non-Metastatic Hepatocellular Carcinoma Unknown status NCT00471484 Phase 2 doxorubicin hydrochloride;fluorouracil;oxaliplatin
19 Phase I/II Study of Autologous Tumor Cell Vaccination Using Metronomic Cyclophosphamide, 3-Dimensional Conformal Radiotherapy, Intra/Peri-Tumor Injection of Poly ICLC With Trans-Hepatic Arterial Embolization Followed by Poly ICLC Boosting in Patients With Unresectable, Recurrent, or Metastatic Cancers in the Liver (Hepatoma, Cholangiocarcinoma, Neuroendocrine, Breast, Colon, Gastric, and Esophageal Cancer) Unknown status NCT00553683 Phase 1, Phase 2 cyclophosphamide;poly ICLC
20 Multicenter, Open-labeled, Controlled Phase II Study: Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma Unknown status NCT02418988 Phase 2 TACE plus rAd-p53 artery injection;TACE
21 Phase II Trial of Bevacizumab Combined With Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma Completed NCT00335829 Phase 2 chemotherapy;embolization therapy
22 A Phase II Study of Trisenox (Arsenic Trioxide) in the Treatment of Unresectable Liver Cancer Completed NCT00128596 Phase 2 arsenic trioxide
23 A Non-Randomized Phase II Study of Sequential Irinotecan (CPT-11) And Flavopiridol In Patients With Advanced Hepatoma Completed NCT00087282 Phase 2 alvocidib;irinotecan hydrochloride
24 Phase I/II Dose Escalation, Pharmacokinetic, Safety, and Efficacy Study of Oral TAC-101 in Patients With Advanced Hepatocellular Carcinoma Completed NCT00077142 Phase 1, Phase 2 TAC-101
25 Thalidomide for Unresectable Hepatocellular Cancer With Optional Interferon Alpha-2a Upon Disease Progression Completed NCT00006006 Phase 2 thalidomide
26 Phase I/II Trial Testing Alpha Fetoprotein (AFP) Peptide Immunization in Hepatocellular Carcinoma Completed NCT00005629 Phase 1, Phase 2
27 A Phase II Study of Octreotide Acetate for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma Completed NCT00257426 Phase 2 octreotide acetate
28 A Phase II Study Of Epirubicin And Thalidomide In Unresectable Or Metastatic Hepatocellular Carcinoma Completed NCT00058487 Phase 2 epirubicin hydrochloride;thalidomide
29 Sho-Saiko-To After Ablation for Non-Resectable Hepatocellular Carcinoma (HCC): A Phase II Trial With Historical Control Completed NCT00040898 Phase 2
30 Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable or Metastatic Hepatocellular Carcinoma Completed NCT00006010 Phase 2 docetaxel;gemcitabine hydrochloride
31 Chemoembolization in Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases: A Phase II Multi-Center Trial Completed NCT00003907 Phase 2 cisplatin;doxorubicin;mitomycin
32 A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer Completed NCT00003557 Phase 2 dolastatin 10
33 Phase I/II Study of Epirubicin and Celecoxib for Hepatocellular Carcinoma Completed NCT00057980 Phase 1, Phase 2 celecoxib;epirubicin hydrochloride
34 A Phase II Study Of Intravenous T900607-Sodium In Subjects With Chemotherapy-Naive Unresectable Hepatocellular Carcinoma Completed NCT00054262 Phase 2 T900607
35 A Phase I/II Trial Testing Immunization With Dendritic Cells Pulsed With Four AFP Peptides in Patients With Hepatocellular Carcinoma Completed NCT00022334 Phase 1, Phase 2
36 A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver Completed NCT00019786 Phase 2 isolated perfusion;melphalan
37 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
38 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
39 Phase II Study of Oxaliplatin, Capecitabine, and Cetuximab in Advanced Hepatocellular Carcinoma Completed NCT00483405 Phase 2 capecitabine;oxaliplatin
40 A Phase II Study Of SB-715992 (NSC 727990) In Patients With Locally Advanced, Recurrent Or Metastatic Hepatocellular Carcinoma Completed NCT00095992 Phase 2 ispinesib
41 A Phase II Study Of rhuMAb VEGF (BEVACIZUMAB) In Patients With Hepatocellular Carcinoma Receiving Chemoembolization Completed NCT00049322 Phase 2
42 A Phase II Study of G3139 in Combination With Doxorubicin in Advanced Hepatocellular Carcinoma Completed NCT00047229 Phase 2 doxorubicin hydrochloride
43 A Low Dose Schedule of Adriamycin and Protracted Infusion of Recombinant Interleukin-2: A Phase II Study of Immunotherapy in Unresectable Hepatocellular Carcinoma Completed NCT00004248 Phase 2 doxorubicin hydrochloride
44 A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Hepatocellular Carcinoma Completed NCT00004108 Phase 2 exatecan mesylate
45 Sorafenib Alone or in Combination With Everolimus in Patients With Unresectable Hepatocellular Carcinoma. A Randomized Multicenter Phase II Trial. Completed NCT01005199 Phase 2 everolimus;sorafenib tosylate
46 Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma Completed NCT00867321 Phase 1, Phase 2 sorafenib tosylate
47 An Investigator Initiated Multicenter Prospective Randomized Study of Chemoembolization Versus Radioembolization for the Treatment of Hepatocellular Carcinoma (PREMIERE Trial) Completed NCT00956930 Phase 2 Doxorubicin
48 Phase II Trial of Intrahepatic Artery Chemotherapy With Nexavar in Hepatocellular Carcinoma Patients Completed NCT00875615 Phase 2 Carboplatin;Cisplatin;Sorafenib
49 Randomized Phase II Trial Assessing the Combination of Nexavar® (Sorafenib), and Gemcitabine/Oxaliplatin in Patients Treated for Advanced (Unresectable/Metastatic) Hepatocellular Carcinoma. Completed NCT00941967 Phase 2 gemcitabine hydrochloride;oxaliplatin;sorafenib tosylate
50 A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) Completed NCT00881751 Phase 2 erlotinib hydrochloride;sorafenib tosylate

Search NIH Clinical Center for Adult Hepatocellular Carcinoma

Genetic Tests for Adult Hepatocellular Carcinoma

Anatomical Context for Adult Hepatocellular Carcinoma

MalaCards organs/tissues related to Adult Hepatocellular Carcinoma:

40
Liver, Endothelial, Colon, Breast

Publications for Adult Hepatocellular Carcinoma

Articles related to Adult Hepatocellular Carcinoma:

(show all 36)
# Title Authors PMID Year
1
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. 6
28677271 2017
2
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
3
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 6
26266985 2015
4
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 6
26266975 2015
5
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
6
Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis. 6
23000435 2013
7
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 6
23100325 2013
8
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 6
22658544 2012
9
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 6
22729222 2012
10
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. 6
17673550 2007
11
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 6
15608678 2005
12
Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas. 6
15531912 2005
13
Mutation of the PIK3CA gene in ovarian and breast cancer. 6
15520168 2004
14
Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. 6
15004724 2004
15
High frequency of mutations of the PIK3CA gene in human cancers. 6
15016963 2004
16
Biallelic inactivation of the APC gene is associated with hepatocellular carcinoma in familial adenomatous polyposis coli. 6
11466687 2001
17
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. 6
10700176 2000
18
Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. 6
10435629 1999
19
Imprinting of the mouse Igf2r gene depends on an intronic CpG island. 6
9722161 1998
20
Isolation of a candidate tumor suppressor gene on chromosome 8p21.3-p22 that is homologous to an extracellular domain of the PDGF receptor beta gene. 6
7898930 1995
21
Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. 6
1349102 1992
22
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. 6
1672732 1991
23
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. 6
1849234 1991
24
Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma. 61
32806748 2020
25
Reactive Ductules Are Associated With Angiogenesis and Tumor Cell Proliferation in Pediatric Liver Cancer. 61
30288475 2018
26
Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: A propensity-matching cohort study. 61
29602016 2018
27
Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma. 61
26990031 2016
28
Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. 61
24002724 2014
29
FAK Inhibition Decreases Hepatoblastoma Survival Both In Vitro and In Vivo. 61
23544173 2013
30
Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. 61
21922643 2012
31
Transcription factor GATA-4 is abundantly expressed in childhood but not in adult liver tumors. 61
21788913 2012
32
Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era. 61
21989430 2011
33
Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. 61
19719772 2009
34
Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. 61
18525461 2008
35
Alpha(1)-antitrypsin deficiency, liver disease and emphysema. 61
12672469 2003
36
Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: comparison study of childhood and adult hepatocellular carcinoma. 61
10847487 2000

Variations for Adult Hepatocellular Carcinoma

ClinVar genetic disease variations for Adult Hepatocellular Carcinoma:

6 (show top 50) (show all 334)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SET NM_003011.4(SET):c.701A>G (p.Glu234Gly) SNV other 438787 rs768759521 GRCh37: 9:131456212-131456212
GRCh38: 9:128693933-128693933
2 TP53 NM_000546.5(TP53):c.96+1G>T SNV Pathogenic 482212 rs1131691003 GRCh37: 17:7579699-7579699
GRCh38: 17:7676381-7676381
3 TERT NM_198253.3(TERT):c.2004G>C (p.Glu668Asp) SNV Pathogenic 268081 rs1554040964 GRCh37: 5:1279532-1279532
GRCh38: 5:1279417-1279417
4 TERT NM_198253.3(TERT):c.337dup (p.Glu113fs) Duplication Pathogenic 268078 rs1554043088 GRCh37: 5:1294663-1294664
GRCh38: 5:1294548-1294549
5 PDGFRL PDGRL, 2-BP DEL Deletion Pathogenic 5469 GRCh37:
GRCh38:
6 AXIN1 NM_003502.4(AXIN1):c.1085_1116del (p.Val362fs) Deletion Pathogenic 6037 rs587776627 GRCh37: 16:359973-360004
GRCh38: 16:309973-310004
7 CASP8 NM_001372051.1(CASP8):c.1226_1227GT[1] (p.Val410fs) Microsatellite Pathogenic 7761 rs587776665 GRCh37: 2:202149961-202149962
GRCh38: 2:201285238-201285239
8 TP53 NM_000546.5(TP53):c.469G>T (p.Val157Phe) SNV Pathogenic 12353 rs121912654 GRCh37: 17:7578461-7578461
GRCh38: 17:7675143-7675143
9 PIK3CA NM_006218.4(PIK3CA):c.3203dup (p.Asn1068fs) Duplication Pathogenic 13658 rs587776802 GRCh37: 3:178952146-178952147
GRCh38: 3:179234358-179234359
10 IGF2R NM_000876.3(IGF2R):c.4346G>T (p.Gly1449Val) SNV Pathogenic 14795 rs121434587 GRCh37: 6:160490993-160490993
GRCh38: 6:160069961-160069961
11 IGF2R NM_000876.3(IGF2R):c.4391G>A (p.Gly1464Glu) SNV Pathogenic 14796 rs121434588 GRCh37: 6:160491038-160491038
GRCh38: 6:160070006-160070006
12 CTNNB1 NM_001904.4(CTNNB1):c.1041_1044del (p.Val349fs) Deletion Pathogenic 801961 rs1575320216 GRCh37: 3:41268801-41268804
GRCh38: 3:41227310-41227313
13 CTNNB1 NM_001904.4(CTNNB1):c.999C>A (p.Tyr333Ter) SNV Pathogenic 450550 rs778624338 GRCh37: 3:41268761-41268761
GRCh38: 3:41227270-41227270
14 CTNNB1 NM_001904.4(CTNNB1):c.1494dup (p.His499fs) Duplication Pathogenic 499655 rs1553631896 GRCh37: 3:41275327-41275328
GRCh38: 3:41233836-41233837
15 APC NM_000038.6(APC):c.1660C>T (p.Arg554Ter) SNV Pathogenic 807 rs137854573 GRCh37: 5:112164586-112164586
GRCh38: 5:112828889-112828889
16 APC NM_000038.6(APC):c.2805C>A (p.Tyr935Ter) SNV Pathogenic 810 rs137854575 GRCh37: 5:112174096-112174096
GRCh38: 5:112838399-112838399
17 APC NM_000038.6(APC):c.3867T>A (p.Cys1289Ter) SNV Pathogenic 545962 rs1554085355 GRCh37: 5:112175158-112175158
GRCh38: 5:112839461-112839461
18 CTNNB1 NM_001904.4(CTNNB1):c.283C>T (p.Arg95Ter) SNV Pathogenic 265443 rs775104326 GRCh37: 3:41266486-41266486
GRCh38: 3:41224995-41224995
19 TP53 NM_000546.6(TP53):c.524G>A (p.Arg175His) SNV Pathogenic 12374 rs28934578 GRCh37: 17:7578406-7578406
GRCh38: 17:7675088-7675088
20 TP53 NM_000546.5(TP53):c.559+1G>A SNV Pathogenic 428908 rs1131691042 GRCh37: 17:7578370-7578370
GRCh38: 17:7675052-7675052
21 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr) SNV Pathogenic 39705 rs121913281 GRCh37: 3:178952084-178952084
GRCh38: 3:179234296-179234296
22 APC NM_000038.6(APC):c.70C>T (p.Arg24Ter) SNV Pathogenic 184702 rs145945630 GRCh37: 5:112090657-112090657
GRCh38: 5:112754960-112754960
23 APC NM_000038.6(APC):c.637C>T (p.Arg213Ter) SNV Pathogenic 140952 rs587781392 GRCh37: 5:112116592-112116592
GRCh38: 5:112780895-112780895
24 APC NM_000038.6(APC):c.646C>T (p.Arg216Ter) SNV Pathogenic 127312 rs62619935 GRCh37: 5:112128143-112128143
GRCh38: 5:112792446-112792446
25 APC NM_000038.6(APC):c.694C>T (p.Arg232Ter) SNV Pathogenic 42248 rs397515734 GRCh37: 5:112128191-112128191
GRCh38: 5:112792494-112792494
26 APC NM_000038.6(APC):c.847C>T (p.Arg283Ter) SNV Pathogenic 184999 rs786201856 GRCh37: 5:112151204-112151204
GRCh38: 5:112815507-112815507
27 APC NM_000038.6(APC):c.933+1G>A SNV Pathogenic 233970 rs876660765 GRCh37: 5:112151291-112151291
GRCh38: 5:112815594-112815594
28 TP53 NM_000546.6(TP53):c.747G>T SNV Pathogenic 12352 rs28934571 GRCh37: 17:7577534-7577534
GRCh38: 17:7674216-7674216
29 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Pathogenic 12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
30 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Pathogenic 12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
31 APC NM_000038.6(APC):c.1695del (p.Val566fs) Deletion Pathogenic 840 rs397514032 GRCh37: 5:112164620-112164620
GRCh38: 5:112828923-112828923
32 CTNNB1 NM_001904.4(CTNNB1):c.134C>T (p.Ser45Phe) SNV Pathogenic/Likely pathogenic 17588 rs121913409 GRCh37: 3:41266137-41266137
GRCh38: 3:41224646-41224646
33 CTNNB1 NM_001904.4(CTNNB1):c.133T>C (p.Ser45Pro) SNV Pathogenic/Likely pathogenic 17589 rs121913407 GRCh37: 3:41266136-41266136
GRCh38: 3:41224645-41224645
34 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Pathogenic/Likely pathogenic 13652 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
35 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Pathogenic/Likely pathogenic 13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
36 TP53 NM_000546.5(TP53):c.517G>A (p.Val173Met) SNV Likely pathogenic 233951 rs876660754 GRCh37: 17:7578413-7578413
GRCh38: 17:7675095-7675095
37 GNAS NM_000516.6(GNAS):c.601C>T (p.Arg201Cys) SNV Likely pathogenic 15933 rs11554273 GRCh37: 20:57484420-57484420
GRCh38: 20:58909365-58909365
38 TP53 NM_000546.6(TP53):c.820G>T SNV Likely pathogenic 376674 rs1057520005 GRCh37: 17:7577118-7577118
GRCh38: 17:7673800-7673800
39 GNAS NM_000516.6(GNAS):c.602G>T (p.Arg201Leu) SNV Likely pathogenic 210045 rs121913495 GRCh37: 20:57484421-57484421
GRCh38: 20:58909366-58909366
40 TP53 NM_000546.6(TP53):c.583A>T SNV Likely pathogenic 376617 rs942158624 GRCh37: 17:7578266-7578266
GRCh38: 17:7674948-7674948
41 TP53 NM_000546.5(TP53):c.641A>G (p.His214Arg) SNV Likely pathogenic 376615 rs1057519992 GRCh37: 17:7578208-7578208
GRCh38: 17:7674890-7674890
42 GNAS NM_000516.6(GNAS):c.602G>A (p.Arg201His) SNV Likely pathogenic 15934 rs121913495 GRCh37: 20:57484421-57484421
GRCh38: 20:58909366-58909366
43 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg) SNV Likely pathogenic 13900 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
44 CREBBP NM_004380.3(CREBBP):c.4336C>T (p.Arg1446Cys) SNV Likely pathogenic 95047 rs398124146 GRCh37: 16:3788618-3788618
GRCh38: 16:3738617-3738617
45 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely pathogenic 12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
46 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Likely pathogenic 12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
47 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser) SNV Likely pathogenic 12365 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
48 TP53 NM_000546.5(TP53):c.526T>A (p.Cys176Ser) SNV Likely pathogenic 376570 rs967461896 GRCh37: 17:7578404-7578404
GRCh38: 17:7675086-7675086
49 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Likely pathogenic 127819 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
50 HRAS , LRRC56 NM_005343.4(HRAS):c.34G>A (p.Gly12Ser) SNV Likely pathogenic 12602 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289

Cosmic variations for Adult Hepatocellular Carcinoma:

9 (show top 50) (show all 15388)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97724722 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 3
2 COSM94430614 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 3
3 COSM94436083 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 3
4 COSM94063771 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 3
5 COSM88264637 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 3
6 COSM102741209 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 3
7 COSM131494492 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.1159A>G p.M387V 22:29049340-29049340 3
8 COSM103081572 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 3
9 COSM95977701 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 3
10 COSM102131817 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 3
11 COSM95960776 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 3
12 COSM113317148 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 3
13 COSM99592496 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 3
14 COSM128686611 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.1072T>A p.F358I 19:36891962-36891962 3
15 COSM123358576 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.691C>T p.L231= 4:145885684-145885684 3
16 COSM123949383 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 3
17 COSM101741672 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 3
18 COSM86004822 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 3
19 COSM98561269 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 3
20 COSM142353152 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 3
21 COSM142221290 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 3
22 COSM99854658 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.156G>A p.V52= 19:52002156-52002156 3
23 COSM139729931 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 3
24 COSM141470046 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 3
25 COSM141819438 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 3
26 COSM145038099 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 3
27 COSM91868668 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 3
28 COSM91880764 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.2171-78T>G p.? 19:30534769-30534769 3
29 COSM140721836 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.2998+205G>A p.? 18:25194955-25194955 3
30 COSM131506983 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 3
31 COSM94799980 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 3
32 COSM90582798 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 3
33 COSM87577038 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 3
34 COSM109096265 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.3433G>T p.V1145L 9:106974156-106974156 3
35 COSM104985080 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.298+23785G>T p.? 2:179745718-179745718 3
36 COSM104427909 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.20G>T p.S7I 2:179745718-179745718 3
37 COSM151538615 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.253+23785G>T p.? 2:179745718-179745718 3
38 COSM127708351 ZNF345 liver,NS,carcinoma,hepatocellular carcinoma c.47-856A>T p.? 19:36891962-36891962 3
39 COSM135887725 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1168C>G p.L390V 16:89734008-89734008 3
40 COSM84511025 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 3
41 COSM111609487 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1444C>G p.L482V 16:89734008-89734008 3
42 COSM92353291 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 3
43 COSM130415812 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.950C>T p.T317I 12:133010889-133010889 3
44 COSM88697750 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 3
45 COSM95253159 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 3
46 COSM94505616 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 3
47 COSM89943752 ZMYM4 liver,NS,carcinoma,hepatocellular carcinoma c.86-8201G>T p.? 1:35350724-35350724 3
48 COSM101398456 ZIC2 liver,NS,carcinoma,hepatocellular carcinoma c.-18C>T p.? 13:99982047-99982047 3
49 COSM113521587 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 3
50 COSM94679661 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 3

Expression for Adult Hepatocellular Carcinoma

Search GEO for disease gene expression data for Adult Hepatocellular Carcinoma.

Pathways for Adult Hepatocellular Carcinoma

Pathways related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.31 TP53 TERT PIK3CA KRAS HRAS GNAS
2
Show member pathways
14.16 TP53 PIK3CA KRAS IGF2R IDH1 HRAS
3
Show member pathways
13.97 TP53 KRAS IGF2R HRAS GNAS FGFR1
4
Show member pathways
13.9 TP53 KRAS IGF2R HRAS GNAS FGFR1
5
Show member pathways
13.85 PIK3CA KRAS IDH1 HRAS FGFR1 CTNNB1
6
Show member pathways
13.82 TP53 KRAS IGF2R HRAS GNAS FGFR1
7
Show member pathways
13.67 KRAS IGF2R HRAS GNAS FGFR1 CTNNB1
8
Show member pathways
13.66 TP53 PIK3CA KRAS HRAS GNAS FGFR1
9
Show member pathways
13.62 PIK3CA KRAS HRAS FGFR1 CTNNB1 CREBBP
10
Show member pathways
13.57 TP53 PIK3CA KRAS HRAS CTNNB1 CREBBP
11
Show member pathways
13.52 PIK3CA KRAS IDH2 HRAS GNAS FGFR1
12
Show member pathways
13.44 KRAS IGF2R HRAS GNAS FGFR1 CREBBP
13
Show member pathways
13.44 KRAS IGF2R HRAS FGFR1 CTNNB1 CREBBP
14
Show member pathways
13.43 TP53 PIK3CA KRAS HRAS GNAS CREBBP
15
Show member pathways
13.4 KRAS HRAS GNAS FGFR1 CTNNB1 CREBBP
16
Show member pathways
13.32 TP53 PIK3CA KRAS HRAS GNAS CTNNB1
17
Show member pathways
13.22 TP53 PIK3CA KRAS HRAS CTNNB1 CREBBP
18
Show member pathways
13.2 TP53 KRAS IGF2R HRAS GNAS FGFR1
19
Show member pathways
13.19 KRAS IGF2R HRAS GNAS FGFR1 CREBBP
20
Show member pathways
13.17 KRAS HRAS GNAS CTNNB1 CREBBP CDKN2A
21
Show member pathways
13.12 TP53 KRAS HRAS GNAS CTNNB1 CREBBP
22
Show member pathways
13.03 KRAS HRAS GNAS CTNNB1 CREBBP CDKN2A
23
Show member pathways
13.03 TP53 PIK3CA KRAS HRAS GNAS CTNNB1
24
Show member pathways
13.02 TERT CTNNB1 CREBBP AXIN1 APC AKT1
25
Show member pathways
13.02 PIK3CA KRAS HRAS GNAS CREBBP AKT1
26
Show member pathways
13.01 PIK3CA KRAS HRAS GNAS FGFR1 CREBBP
27
Show member pathways
12.93 TP53 PIK3CA CREBBP CASP8 AKT1
28
Show member pathways
12.91 KRAS HRAS GNAS CTNNB1 AKT1
29 12.91 TP53 KRAS HRAS FGFR1 CASP8 AKT1
30
Show member pathways
12.89 TP53 PIK3CA KRAS HRAS FGFR1 CTNNB1
31
Show member pathways
12.88 PIK3CA KRAS HRAS GNAS AKT1
32
Show member pathways
12.87 TP53 PIK3CA KRAS HRAS FGFR1 AKT1
33
Show member pathways
12.87 PIK3CA KRAS HRAS GNAS FGFR1 CTNNB1
34
Show member pathways
12.86 PIK3CA HRAS CTNNB1 CASP8 AKT1
35
Show member pathways
12.85 TP53 PIK3CA KRAS HRAS CTNNB1 APC
36
Show member pathways
12.83 TP53 PIK3CA KRAS HRAS CDKN2A CASP8
37
Show member pathways
12.82 PIK3CA KRAS HRAS GNAS CREBBP AKT1
38
Show member pathways
12.8 TP53 PIK3CA KRAS HRAS GNAS FGFR1
39
Show member pathways
12.79 TP53 KRAS HRAS CREBBP AKT1
40
Show member pathways
12.78 PIK3CA KRAS HRAS GNAS CTNNB1 AKT1
41 12.77 PIK3CA KRAS HRAS FGFR1 APC
42
Show member pathways
12.77 TP53 PIK3CA KRAS HRAS CREBBP AKT1
43
Show member pathways
12.74 TP53 PIK3CA KRAS HRAS CTNNB1 AKT1
44
Show member pathways
12.73 TP53 TERT PIK3CA KRAS HRAS FGFR1
45 12.67 TP53 PIK3CA KRAS HRAS CREBBP CDKN2A
46
Show member pathways
12.62 PIK3CA KRAS HRAS CREBBP AKT1
47
Show member pathways
12.62 TP53 PIK3CA KRAS HRAS FGFR1 CTNNB1
48
Show member pathways
12.62 TP53 PIK3CA KRAS IGF2R HRAS FGFR1
49
Show member pathways
12.61 GNAS CTNNB1 AXIN1 APC AKT1
50
Show member pathways
12.6 TP53 TERT PIK3CA KRAS HRAS GNAS

GO Terms for Adult Hepatocellular Carcinoma

Cellular components related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.3 TP53 TERT IGF2R HRAS GNAS FGFR1
2 cytoplasm GO:0005737 10.16 TP53 TERT PIK3CA KRAS IDH1 HRAS
3 mitochondrion GO:0005739 9.97 TP53 TERT KRAS IDH2 IDH1 CDKN2A
4 protein-containing complex GO:0032991 9.88 TP53 CTNNB1 CNOT9 CDKN2A CASP8 AKT1
5 perinuclear region of cytoplasm GO:0048471 9.7 PIK3CA IGF2R HRAS GNAS CTNNB1 AXIN1
6 lamellipodium GO:0030027 9.62 PIK3CA CTNNB1 APC AKT1
7 lateral plasma membrane GO:0016328 9.61 CTNNB1 AXIN1 APC
8 cytosol GO:0005829 9.53 TP53 TERT PIK3CA KRAS IDH2 IDH1
9 beta-catenin destruction complex GO:0030877 9.13 CTNNB1 AXIN1 APC

Biological processes related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 10.07 TP53 HRAS CDKN2A CASP8 AXIN1 AKT1
2 negative regulation of cell proliferation GO:0008285 10.02 TP53 HRAS CTNNB1 CDKN2A APC
3 positive regulation of gene expression GO:0010628 9.99 TP53 KRAS HRAS CTNNB1 CDKN2A AKT1
4 positive regulation of transcription, DNA-templated GO:0045893 9.98 TP53 CTNNB1 CREBBP CNOT9 CDKN2A AXIN1
5 negative regulation of gene expression GO:0010629 9.95 TP53 TERT HRAS CTNNB1 AKT1
6 cytokine-mediated signaling pathway GO:0019221 9.92 TP53 PIK3CA KRAS CNOT9 AKT1
7 positive regulation of protein phosphorylation GO:0001934 9.91 KRAS HRAS AXIN1 AKT1
8 negative regulation of neuron apoptotic process GO:0043524 9.86 TERT PIK3CA KRAS HRAS
9 cell cycle arrest GO:0007050 9.84 TP53 HRAS CDKN2A APC
10 positive regulation of MAP kinase activity GO:0043406 9.78 KRAS HRAS FGFR1
11 regulation of cell differentiation GO:0045595 9.76 FGFR1 CTNNB1 APC
12 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.71 PIK3CA CNOT9 AXIN1 AKT1
13 beta-catenin-TCF complex assembly GO:1904837 9.67 TERT CTNNB1 CREBBP
14 liver development GO:0001889 9.67 PIK3CA KRAS IGF2R HRAS
15 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.64 TP53 TERT
16 anoikis GO:0043276 9.63 PIK3CA AKT1
17 NADP metabolic process GO:0006739 9.63 IDH2 IDH1
18 positive regulation of nitric-oxide synthase activity GO:0051000 9.63 TERT KRAS AKT1
19 response to isolation stress GO:0035900 9.62 KRAS HRAS
20 isocitrate metabolic process GO:0006102 9.6 IDH2 IDH1
21 beta-catenin destruction complex assembly GO:1904885 9.58 AXIN1 APC
22 hair follicle placode formation GO:0060789 9.57 GNAS CTNNB1
23 Ras protein signal transduction GO:0007265 9.56 TP53 KRAS HRAS CDKN2A
24 beta-catenin destruction complex disassembly GO:1904886 9.5 CTNNB1 AXIN1 APC
25 glyoxylate cycle GO:0006097 9.48 IDH2 IDH1
26 regulation of apoptotic process GO:0042981 9.43 TP53 IGF2R CTNNB1 CREBBP CASP8 AKT1
27 replicative senescence GO:0090399 9.33 TP53 TERT CDKN2A
28 positive regulation of apoptotic process GO:0043065 9.17 TP53 IGF2R CTNNB1 CDKN2A CASP8 APC

Molecular functions related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.91 TP53 TERT KRAS IGF2R IDH1 FGFR1
2 protein homodimerization activity GO:0042803 9.85 TERT IDH1 FGFR1 CNOT9 AXIN1 AKT1
3 enzyme binding GO:0019899 9.83 TP53 IGF2R CTNNB1 AXIN1 AKT1
4 p53 binding GO:0002039 9.63 TP53 CREBBP CDKN2A
5 protein kinase binding GO:0019901 9.63 TP53 CTNNB1 CDKN2A AXIN1 APC AKT1
6 RNA polymerase II transcription factor binding GO:0001085 9.58 TP53 CTNNB1 CREBBP
7 disordered domain specific binding GO:0097718 9.5 TP53 CTNNB1 CDKN2A
8 MDM2/MDM4 family protein binding GO:0097371 9.48 TP53 CDKN2A
9 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH2 IDH1
10 isocitrate dehydrogenase activity GO:0004448 8.62 IDH2 IDH1

Sources for Adult Hepatocellular Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....